Labeled iodinated tropane formulation
AssigneeAlseres Pharmaceuticals, Inc.
InventorsChris Sterzinger, Cara Ferreira, David Leyh, Richard Thorn
Life of this patent
Estimating the term…
Abstract
A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [123I]-2β-carbomethoxy-3β-(4-flurophenyl)-N-(3-iodo-E-allyl) nortropane.
Claims16
A formulation comprising an aqueous solution comprising [123I]-2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl) nortropane, wherein the solution comprises a radioactive concentration of at least about 18 mCi/mL, wherein the [123I]-2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl) nortropane is stable for at least 48 hours.
A formulation comprising an aqueous solution comprising [123I]-2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl) nortropane, wherein the solution comprises a radioactive concentration of at about 4 mCi/mL, wherein the [123I]-2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl) is stable for at least 48 hours.
A formulation comprising an aqueous solution comprising [123I]-2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl) nortropane, wherein the solution comprises a radioactive concentration of at about 16 mCi/mL, wherein the [123I]-2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl) is stable for at least 48 hours.
A formulation comprising an aqueous solution comprising [123I]-2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl) nortropane, wherein the formulation exhibits radioactive concentration of at least about 1.6 mCi/mL at least about 51 hours post creation, wherein the [123I]-2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl) is stable for at least 48 hours.
Dependencies are inferred from the claim text.